Company Overview
MetaVia Inc. operates as a clinical-stage biotechnology entity dedicated to the development of novel pharmaceutical compounds designed to address cardiometabolic diseases. The company's primary strategic focus involves the advancement of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, which possesses development optionality to function either as a standalone therapy or in combination with other treatments currently in Phase 2a clinical trials. This company is situated within the broader Healthcare sector and the specific Biotechnology industry, classifications that define its regulatory environment and research-intensive operational model. In terms of scale, MetaVia Inc. holds a market capitalization of $6.21M, while its annual revenue and employee count are listed as N/A within the provided financial data. These valuation figures indicate that the company is a small-cap entity operating with limited financial resources, a status typical for clinical-stage firms that prioritize capital allocation toward research and development rather than revenue generation or workforce expansion.
Financial Health
The company reports net income of $-12,973,000 for the trailing twelve months, with EBITDA standing at $-13,689,000 and revenue figures listed as N/A. The absence of reported revenue alongside significant net losses reveals a cost structure heavily weighted toward research, development, and clinical trial expenses rather than commercial sales activities. Free cash flow for the period was $-11,721,500, indicating a negative cash flow trajectory that reflects the substantial cash burn associated with advancing pre-commercial assets through clinical phases. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a status that signifies the company is not yet profitable and has not generated sufficient revenue to cover its operational and production costs. Regarding liquidity and leverage, the company holds cash reserves of $10.28M against a debt load of $210,000, resulting in a debt-to-equity ratio of 3.94. Despite the relatively low absolute debt, the high debt-to-equity ratio suggests a leveraged capital structure relative to its equity base, though the low absolute debt amount mitigates immediate refinancing risk. The current ratio is 1.93, which indicates that the company possesses 1.93 dollars in current assets for every dollar of current liabilities, suggesting adequate short-term liquidity to meet its obligations. Return on Equity is -195.6% and Return on Assets is -62.6%, metrics that reveal management is currently utilizing shareholder and asset bases to generate negative returns, a common characteristic of early-stage biotechnology companies investing heavily in pipeline development.
Valuation Assessment
Trailing P/E and forward P/E ratios are listed as N/A due to the company's lack of earnings, implying that traditional earnings-based valuation models are not applicable at this stage of the company's lifecycle. The price-to-book ratio stands at 0.18, which indicates that the market values the company at less than 20% of its book value, suggesting a significant discount relative to its net asset position. Price-to-sales ratio and EV/EBITDA are also N/A or 0.28 respectively, with the EV/EBITDA of 0.28 suggesting an extremely low multiple that reflects the high risk and lack of profitability inherent in clinical-stage assets. The stock has experienced a wide trading range, with a 52-week high of $23.10 and a 52-week low of $1.21. Without a specific current price provided in the source data, the position relative to the high and low cannot be precisely calculated as a percentage, but the range of over 18x indicates extreme volatility. Beta is listed as N/A, meaning volatility data relative to the broader market is not available to quantify the stock's sensitivity to market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding any calculation of whether earnings are growing faster or slower than revenue. Because the company is not a dividend payer, the dividend yield and payout ratio are N/A and 0.0% respectively. This absence of a dividend distribution implies that the company reinvests all available capital, including its cash reserves, back into research, development, and clinical trials rather than returning value to shareholders via income payments. The overall growth and income profile is characterized by a lack of historical financial growth data and a complete absence of dividend income, positioning the investment purely as a high-risk, high-potential growth play dependent on future clinical trial successes rather than current earnings or cash distributions.